Scarica l'app Stockscreener
38.75
0.68%
0.26
Dopo l'orario di chiusura:
38.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$38.49
Aprire:
$39.6
Volume 24 ore:
613.00K
Relative Volume:
0.97
Capitalizzazione di mercato:
$2.31B
Reddito:
$45.48M
Utile/perdita netta:
$169.95M
Rapporto P/E:
14.79
EPS:
2.62
Flusso di cassa netto:
$230.85M
1 W Prestazione:
+0.21%
1M Prestazione:
+1.71%
6M Prestazione:
-6.74%
1 anno Prestazione:
+44.70%
Intervallo 1D:
$38.44
$39.90
Intervallo di 1 settimana:
$37.50
$39.90
Portata 52W:
$24.22
$48.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Confronta PTGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
38.75 | 2.31B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics, Inc SEC 10-K Report - TradingView
Hussman Strategic Advisors Inc. Purchases New Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics: Q4 Earnings Snapshot - The Advocate
Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 License, Collaboration Revenue $170.6M - Marketscreener.com
Earnings Flash (PTGX) Protagonist Therapeutics Posts Q4 EPS $1.98 -February 21, 2025 at 07:14 am EST - Marketscreener.com
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - ACCESS Newswire
AlphaCentric Advisors LLC Decreases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics CEO Dinesh Patel sells shares worth $204,606 By Investing.com - Investing.com Australia
Protagonist Therapeutics (PTGX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Stocks Generating Improved Relative Strength: Protagonist Therapeutics - MSN
Protagonist Therapeutics CEO Dinesh Patel sells shares worth $204,606 - Investing.com India
Protagonist Therapeutics CEO Sells Shares to Cover Tax Obligation - TradingView
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
(PTGX) Proactive Strategies - Stock Traders Daily
Louisiana State Employees Retirement System Acquires 300 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com Australia
Protagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical milestones - Investing.com Nigeria
Jefferies maintains Buy on Protagonist Therapeutics, $57 target - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Yousif Capital Management LLC - Defense World
Will Weakness in Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock Prove Temporary Given Strong Fundamentals? - Simply Wall St
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) PT at $56.00 - MarketBeat
Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now - Insider Monkey
Bleakley Financial Group LLC Has $246,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $56.00 Average PT from Brokerages - Defense World
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
Protagonist Therapeutics' (PTGX) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Taking the lead: Protagonist Therapeutics Inc (PTGX) - SETE News
HC Wainwright Reaffirms "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Polycythemia Vera Market Predicted to See Upsurge Through 2034, - openPR
Protagonist Therapeutics’ (PTGX) “Buy” Rating Reiterated at HC Wainwright - Defense World
JMP Securities Reiterates “Market Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX) - ETF Daily News
Protagonist Therapeutics’ (PTGX) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Given Market Outperform Rating at JMP Securities - Armenian Reporter
Objective long/short (PTGX) Report - Stock Traders Daily
Truist maintains Buy on Protagonist Therapeutics with $60 target - MSN
Truist maintains Buy on Protagonist Therapeutics with $60 target By Investing.com - Investing.com UK
JMP Securities maintains PTGX stock with $58 target - MSN
Caprock Group LLC Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Selling Buzz: Protagonist Therapeutics Inc [PTGX] Chief Medical Officer MOLINA ARTURO MD sells 26,000 shares of the company – Knox Daily - Knox Daily
Financial Metrics Check: Protagonist Therapeutics Inc (PTGX)’s Ratios for Trailing Twelve Months - The Dwinnex
Protagonist Therapeutics Inc (PTGX) deserves closer scrutiny - US Post News
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $53.00 - MarketBeat
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Increased by Nisa Investment Advisors LLC - Defense World
Top Cancer Experts to Review Game-Changing Blood Disorder TreatmentHere's What's Coming - StockTitan
Protagonist Receives $34 Million from Warrant Exercises - ACCESS Newswire
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):